Volume 2.32 | Sep 2

Prostate Cell News 2.32, September 2, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer (CRPC) and is Upregulated by Treatment with CYP17A1 Inhibitors
Results of this study indicate that CRPCs resistant to CYP17A1 inhibition may remain steroid dependent and therefore responsive to therapies that can further suppress de novo intratumoral steroid synthesis. [Cancer ResAbstract

PUBLICATIONS (Ranked by Impact Factor of the Journal)


Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-Epithelial Glycoprotein-1 Monoclonal Antibody
In this study, the characteristics of hRS7 for targeting prostate cancer were examined. [J Nucl Med] Abstract

A Novel Membrane-Associated Androgen Receptor (AR) Splice Variant Potentiates Proliferative and Survival Responses in Prostate Cancer Cells
Researchers report the identification of a novel AR splice variant, designated as AR8, which is upregulated in castration-resistant prostate cancer cells. [J Biol ChemAbstract

A Transductionally Re-Targeted Adenovirus Vector for Virotherapy of Her2/neu Expressing Prostate Cancer
Researchers show that the oncolytic Ad[ZH/3] vector significantly prolonged survival time and reduced serum prostate-specific antigen levels in an orthotopic prostate tumor model in nude mice to the same extent as wild type Ad5. [Hum Gene Ther] Abstract

Human Kallikrein 4 (KLK4) Signal Peptide Induces Cytotoxic T cell Responses in Healthy Donors and Prostate Cancer Patients
Researchers identified a naturally processed, HLA-A*0201-restricted peptide epitope within the signal sequence region of KLK4 that induced cytotoxic T lymphocytes responses in vitro in most healthy donors and prostate cancer patients tested. [Cancer Immunol Immunother] Abstract

Molecular Targeting of Prostate Cancer Cells by a Triple Drug Combination Down-Regulates Integrin Driven Adhesion Processes, Delays Cell Cycle Progression and Interferes with the Cdk-Cyclin Axis
In the present study, the combined impact of the mammalian target of rapamycin-inhibitor RAD001, the dual epidermal growth factor receptor and vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 and the histone deacetylase-inhibitor valproic acid on prostate cancer growth and adhesion in vitro was investigated. [BMC Cancer] Abstract

Imatinib Mesylate (Gleevec) as Protein-Tyrosine Kinase Inhibitor Elicits Smooth Muscle Relaxation in Isolated Human Prostatic Tissue
The objective of this study was to evaluate the mechanism of action of Gleevec, a protein tyrosine kinase inhibitor on the human prostate with benign prostatic hyperplasia. [Urology] Abstract


PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Researchers validate a simple method to interrogate PTEN status in clinical specimens and support the utility of this test in future multi-center studies, clinical trials and ultimately perhaps for routine clinical care. [Clin Cancer ResAbstract

Prostate Cancer: Prediction of Biochemical Failure after External-Beam Radiation Therapy – Kattan Nomogram and Endorectal MR Imaging Estimation of Tumor Volume
The purpose of this study was to determine whether magnetic resonance (MR) imaging and MR spectroscopic imaging findings can improve predictions made with the Kattan nomogram for radiation therapy. [Radiology] Abstract

Long-Term Biochemical Control of Prostate Cancer after Standard or Hyper-Fractionation: Evidence for Different Outcomes between Low–Intermediate and High Risk Patients
The purpose of this study was to report the long-term biochemical control of a non-randomized trial comparing standard and hyper-fractionated radiation schedules for prostate cancer treatment. [Radiother Oncol] Abstract

Does the Transrectal Ultrasound Probe Influence Prostate Cancer Detection in Patients Undergoing an Extended Prostate Biopsy Scheme? Results of a Large Retrospective Study
The objective of this study was to compare the prostate cancer detection rate and tolerance profile between a transrectal biopsy made with a ‘side fire’ and an ‘end fire’ ultrasound probe. [BJU Int] Abstract



Food and Drug Administration (FDA) Approves Dendreon’s Atlanta Cancer Immunotherapy Manufacturing Facility
Dendreon Corporation announced that the U.S. FDA approved its Atlanta cancer immunotherapy manufacturing facility, the third location at which the company will produce PROVENGE® (sipuleucel-T) to help meet the needs of patients across the U.S. with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. [Dendreon Corporation] Press Release

University of Southern Carolina (USC) Institute of Urology Adds New Technology
Detection of prostate cancer just became more accurate at the USC Institute of Urology, thanks to the addition of new technology, some of the first available in the United States. [University of Southern Carolina] Press Release

Britain to Launch Personalized Medicine Project – Pilot Programme Will Combine Genetic Tests with Centralized Data
Led by the charity Cancer Research UK, the Stratified Medicine Program will enroll 9,000 people with breast, colorectal, lung, prostate, ovarian and skin cancer in the first, two-year phase of the project. [NatureNews] Press Release

Adamis Pharmaceuticals Begins Prostate Cancer Trial
Adamis Pharmaceuticals Corporation announced that it enrolled the first patient in its Phase 1/2a clinical prostate study. [Business Wire] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 7th Annual Stem Cell Summit 
February 21, 2012 
New York, United States 

NEW International Society for Stem Cell Research 10th Annual Meeting 
June 13-16, 2012 
Yokohama, Japan


Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Prostate Cancer Scientist (McGill University Health Centre) 

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoctoral Position – Stem Cells and Immunology (University of Connecticut)  

Postdoctoral Fellow in Prostate Cancer Research (University of Texas Southwestern Medical Center)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us